Research into a nano-amorphous approach suggests a new breakthrough in Crohn’s management may come from a shift toward modulating the biophysical environment of the gut.
- From IV To Subcutaneous: It's Not About Convenience, It's About System Design
- 6 Packaging And Delivery Challenges For Biologic Therapies
- Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
- Nanosystems And Rare Diseases: Opportunities And Limitations
- 3 Emerging Trends In Drug Delivery Device Pipelines
- Organic Impurities: New Draft ICH Q3E Guidance For Leachables And Extractables
- Closing The Adherence Gap: The Connected Health Era
- Delivery Strategy For Next-Gen Cardiac Gene Therapies
ON-DEMAND WEBINARS
Using volatile processing aids to increase drug solubility in more environmentally friendly solvents, like methanol, reduces the amount of solvent required to manufacture amorphous solid dispersions (ASDs).
Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.
Discover highly promising in-vivo data, enabled by a nanoformed drug product for the treatment of glioblastoma multiforme (GBM).
"One stop” sterile injectable fill/finish capabilities can accelerate timelines and reduce costs. Explore August Bio’s operational flexibility and available capacity to support small-, mid-size, and large-scale batches.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![MDO 2 - GC_APP_Photoshoot 2021 Vials Glamour V9 various sizes and colored seals]( "FAQs On The Revised EU GMP Annex 1: Volume 2")
FAQs On The Revised EU GMP Annex 1: Volume 2Review the implementation of a holistic Contamination Control Strategy (CCS). Discover four key considerations for assessing component readiness: product, process, protection, and proof.
-
![GettyImages-2036497686-lab-team-collaboration-laboratory-tablet-computer]( "Navigating PFAS In Medical Devices")
Navigating PFAS In Medical DevicesReview how an experienced partner can help you navigate the shifting regulatory landscape for your medical device.
-
![drug delivery trends]( "Trends In Drug Delivery: The Growth Of Cartridge Based Technology")
Trends In Drug Delivery: The Growth Of Cartridge Based TechnologyAs pharma companies evaluate the delivery systems for their drug product, there are several reasons why they may select a cartridge-based system compared to a pre-filled syringe or vial.
-
![GettyImages-950086574-oral-solid-OSD-pill-tablet-capsule-development]( "Choosing A Formulation And Process Approach To OCR Products")
Choosing A Formulation And Process Approach To OCR ProductsDo you want to develop an oral controlled release (OCR) product? Understand the options and their ramifications as the first step toward devising a plan.
-
![GettyImages-1441662840-lab-team-communication-collaboration]( "Partnership Goals For Scale-Up Success")
Partnership Goals For Scale-Up SuccessAs demand for capabilities and resources grows throughout a project, both become strained in-house and the scale-up process becomes a steeper hill to climb.
-
![GettyImages-1371993517-syringe-vial-mask-vaccine-inject]( "Advancing Chronic Care Through GLP‑1 Innovation")
Advancing Chronic Care Through GLP‑1 InnovationGLP‑1 therapies are changing injectable care and driving rapid progress in delivery and manufacturing. See how patient needs, emerging tech, and regulations are reshaping chronic treatment.
-
![iStock-1191189866-lung-inhalation-skeleton-respiratory]( "Expanding Opportunities For Inhaled Drug Delivery")
Expanding Opportunities For Inhaled Drug DeliveryReview the challenges and intricacies of effectively delivering drugs to the lung and the advantages of using nanoparticles and gentle particle processing techniques to enable delivery of sensitive drugs.
-
![iStock-827580992-lab-research-development]( "Overcoming Limitations To Achieve Uniform Dosing")
Overcoming Limitations To Achieve Uniform DosingAn immediate need for lower dose capsules in the clinic posed several challenges in blend formulation with very tight timelines for delivery.
-
![Compliance GettyImages-1348548209]( "Annex 1 – The Brave New World Of Regulatory Compliance")
Annex 1 – The Brave New World Of Regulatory ComplianceThe revision to Annex 1 will become effective in August 2023. Explore the major changes and considerations along with the next steps to achieve Annex 1 Regulatory compliance.
-
![iStock-1287080337-lab-microscope-scientist-research.jpg]( "Integrated First-In-Human Services To Streamline End-To-End Development And Manufacturing")
Integrated First-In-Human Services To Streamline End-To-End Development And ManufacturingLonza’s SimpliFiH®️ Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.
DELIVERED BY DEGRAZIO
-
![Delivered _by _DeGrazio_Logo_Color_2]( "6 Packaging And Delivery Challenges For Biologic Therapies")
6 Packaging And Delivery Challenges For Biologic TherapiesIn this article, Fran DeGrazio identifies six aspects of biologics-based therapy packaging and delivery that, if addressed, may help to ensure successful product development and lifecycle management. They include 1) chemical compatibility with device functionality, 2) long-acting formulations, 3) product stability, 4) primary packaging and device integration, 5) cold storage, and 6) higher concentrations and viscosities.
FREE EBOOK: COMBINATION PRODUCTS
Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.
